logo BDSP

Base documentaire


Votre avis nous intéresse

Le réseau BDSP met en oeuvre un projet d'innovation et d'amélioration de ses services, dans le souci constant de proposer des contenus de qualité adaptés aux besoins des utilisateurs.

Identifier de nouvelles sources de financements est la condition nécessaire pour assurer la poursuite et la pérennité de cet outil unique qu'est la BDSP, tout en le faisant évoluer.

Pour définir un nouveau modèle économique, nous avons besoin de votre avis : merci de répondre à notre enquête (temps estimé : 5 minutes).

Participer maintenant
Participer plus tard J'ai déjà participé

  1. Fulltext. Estimating the benefits of modifying risk factors of cardiovascular disease : A comparison of primary vs secondary prevention.

    Article - En anglais

    Fulltext.

    Objectives 

    To compare the potential years of life saved (YOLS) associated with risk factor modification in the primary and secondary prevention of cardiovascular disease (CVD).

    Methods 

    The CVD life expectancy model estimates the risk of death due to coronary disease, stroke, and other causes based on the levels of independent risk factors (such as age, blood pressure, and blood lipid levels) found in the cohort of the Lipid Research Clinics.

    The model was validated by comparing its predictions with the observed fatal outcomes of 9 randomized clinical trials.

    We then estimated the YOLS associated with treating hyperlipidemia or hypertension among hypothetical patient groups with and without CVD at baseline.

    We defined high-risk patients as those with 3 risk factors (hyperlipidemia, cigarette smoking, and hypertension) and low-risk patients as those with isolated hypertension or hyperlipidemia.

    Results 

    The fatal events predicted by the model were consistent with the clinical trial results.

    Among men and women with hyperlipidemia without CVD, the forecasted benefits of lipid therapy were substantially greater among high-risk groups vs low-risk groups (4.74-0.78 YOLS vs 2.50-0.25 YOLS, respectively).

    Among those with CVD, the forecasted benefits of treatment were similar for both high-risk and low-risk groups (4.65-0.65 YOLS vs 3.84-0.58 YOLS, respectively). (...)

    Mots-clés Pascal : Cardiopathie, Etude comparative, Facteur risque, Modification procédé, Prévention, Analyse avantage coût, Qualité vie, Homme, Appareil circulatoire pathologie

    Mots-clés Pascal anglais : Heart disease, Comparative study, Risk factor, Process modification, Prevention, Cost benefit analysis, Quality of life, Human, Cardiovascular disease

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 98-0177602

    Code Inist : 002B12A09. Création : 11/09/1998.